CLOLAR

LOE Approaching

clofarabine

NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

5'-monophosphate metabolite by deoxycytidine kinase and mono- and di-phospho-kinases to the active 5'-triphosphate metabolite. Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine. Clofarabine…

Clinical Trials (5)

NCT07156435Phase 1Recruiting

Vyxeos® With Clofarabine for Pediatric AML

Started Nov 2020
25 enrolled
Relapsed Pediatric AMLRefractory Pediatric AML
NCT02425904Phase 2Active Not Recruiting

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Started May 2015
25 enrolled
Langerhans Cell Histiocytosis
NCT01900509Phase 1Completed

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Started Aug 2013
16 enrolled
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
NCT01629082Phase 1Completed

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Started Jun 2012
4 enrolled
Myeldysplastic Syndrome (MDS)Chronic Myelomonocytic LeukemiaBone Marrow Diseases+2 more
NCT01534702Phase 1/2Unknown

Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML

Started Jan 2012
60 enrolled
Acute Myeloid Leukemia